Our data suggest that EGFR may be a therapeutic target for obesity-related cardiovascular diseases, and that the novel EGFR inhibitor 542 shows promises to the treatment on obesity-induced cardiac complications. This evidence concerns the gene EGFR and obesity due to melanocortin 4 receptor deficiency.